{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T20:58:22Z","timestamp":1785445102964,"version":"3.56.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bayer AG, DZHK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Persistent cardiac symptoms are common in post-COVID syndrome, even without structural heart disease. Evidence implicates immune dysregulation, endothelial dysfunction and low-grade cardiovascular inflammation. Yet no targeted treatment exists. Myoflame-19 is a multicenter, double-blind clinical trial of 279 participants with inflammatory cardiac involvement defined by cardiovascular magnetic resonance, randomized 1:1 to losartan plus prednisolone (\n                    <jats:italic>n\u2009=\u2009139<\/jats:italic>\n                    ) or matching placebos (\n                    <jats:italic>n\u2009=\u2009140<\/jats:italic>\n                    ) for 16 weeks. The modified intention-to-treat population comprised 124 and 122 participants. The primary endpoint, change in left ventricular (LV) ejection fraction, was neutral: between-group difference 0.74 percentage points (pp), 95%CI \u22120.14 to 1.62, p\u2009=\u20090.10, unpaired t-test; supportive baseline-adjusted ANCOVA 0.99, 95%CI 0.15-1.83, p\u2009=\u20090.021. Among prespecified secondary endpoints, several symptom and imaging measures showed numerical differences favoring intervention, including Average Symptom Score components (modified Canadian Chest Pain Scale \u22124.8 pp, 95%CI \u221217.3 to 7.6; NYHA class \u22128.1 pp, \u221220.6 to 4.3; Long COVID symptom burden \u22127.7 pp, \u221218.9 to 3.6), native T1 and T2 values (native T1 \u22122.46\u2009ms, \u22128.35 to 3.42; native T2 \u22120.31\u2009ms, \u22121.16 to 0.53), and LV end-diastolic volume (\u2009+\u20091.45\u2009ml\/m\u00b2, \u22120.09 to 3.00); however, confidence intervals included the null value and these findings should be regarded as hypothesis-generating.Treatment was safe and well-tolerated. These findings indicate a neutral treatment effect on the primary endpoint. They inform targeted immunomodulation and design of future trials in post-COVID syndrome and inflammatory cardiac involvement. Trial registration: EudraCT 2022-001682-12; NCT05619653.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-75991-w","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T02:56:29Z","timestamp":1785380189000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Losartan and prednisolone for post-COVID syndrome and cardiac inflammation: a randomized, double-blind, placebo-controlled trial"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6044-7002","authenticated-orcid":false,"given":"Valentina O.","family":"Puntmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6044-950X","authenticated-orcid":false,"given":"Eike","family":"Nagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3179-3827","authenticated-orcid":false,"given":"Dietrich","family":"Beitzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kammerlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Voges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7471-475X","authenticated-orcid":false,"given":"Marcus","family":"Doerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bishwas","family":"Chamling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6362-0253","authenticated-orcid":false,"given":"Biykem","family":"Bozkurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Kaski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Spatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gernot","family":"Rohde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"DeLeuw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Windemuth-Kieselbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Eckhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7766-6167","authenticated-orcid":false,"given":"Peter C.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4547-8636","authenticated-orcid":false,"given":"Colin","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"75991_CR1","doi-asserted-by":"crossref","unstructured":"Gluckman, T. J. et al. Writing Committee. 2022 ACC expert consensus decision pathway on cardiovascular sequelae of COVID-19 in adults: myocarditis and other myocardial involvement, post-acute sequelae of SARS-CoV-2 infection, and return to play. J. Am. Coll. Cardiol. 79, 1717\u2013 1756 (2022).","DOI":"10.1016\/j.jacc.2022.02.003"},{"key":"75991_CR2","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1038\/s41591-021-01433-3","volume":"27","author":"B Blomberg","year":"2021","unstructured":"Blomberg, B. et al. Long COVID in a prospective cohort of home-isolated patients. Nat. Med. 27, 1607\u20131613 (2021).","journal-title":"Nat. Med."},{"key":"75991_CR3","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1038\/s41591-022-02000-0","volume":"28","author":"VO Puntmann","year":"2022","unstructured":"Puntmann, V. O. et al. Long-term cardiac pathology in individuals with mild initial COVID-19 illness. Nat. Med. 28, 2117\u20132123 (2022).","journal-title":"Nat. Med."},{"key":"75991_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32507-6","volume":"13","author":"C Kedor","year":"2022","unstructured":"Kedor, C. et al. A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity. Nat. Commun. 13, 5104 (2022).","journal-title":"Nat. Commun."},{"key":"75991_CR5","doi-asserted-by":"publisher","first-page":"5500","DOI":"10.1016\/j.cell.2024.07.054","volume":"187","author":"MJ Peluso","year":"2024","unstructured":"Peluso, M. J. & Deeks, S. G. Mechanisms of long COVID and the path toward therapeutics. Cell 187, 5500\u20135529 (2024).","journal-title":"Cell"},{"key":"75991_CR6","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/s41577-023-00904-7","volume":"23","author":"DM Altmann","year":"2023","unstructured":"Altmann, D. M., Whettlock, E. M., Liu, S., Arachchillage, D. J. & Boyton, R. J. The immunology of long COVID. Nat. Rev. Immunol. 23, 618\u2013634 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"75991_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53356-5","volume":"15","author":"AF Jernbom","year":"2024","unstructured":"Jernbom, A. F. et al. Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19. Nat. Commun. 15, 8941 (2024).","journal-title":"Nat. Commun."},{"key":"75991_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28905-5","volume":"13","author":"O Cabral-Marques","year":"2022","unstructured":"Cabral-Marques, O. et al. Autoantibodies targeting GPCRs and RAS-related molecules associate with COVID-19 severity. Nat. Commun. 13, 1220 (2022).","journal-title":"Nat. Commun."},{"key":"75991_CR9","doi-asserted-by":"publisher","first-page":"e28273","DOI":"10.1002\/jmv.28273","volume":"95","author":"E Hallmann","year":"2023","unstructured":"Hallmann, E. et al. IgG autoantibodies against ACE2 in SARS-CoV-2 infected patients. J. Me\u0301d. Virol. 95, e28273 (2023).","journal-title":"J. Me\u0301d. Virol."},{"key":"75991_CR10","doi-asserted-by":"publisher","first-page":"103402","DOI":"10.1016\/j.autrev.2023.103402","volume":"22","author":"A Akbari","year":"2023","unstructured":"Akbari, A. et al. COVID-19, G protein-coupled receptor, and renin-angiotensin system autoantibodies: systematic review and meta-analysis. Autoimmun. Rev. 22, 103402 (2023).","journal-title":"Autoimmun. Rev."},{"key":"75991_CR11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41586-023-06651-y","volume":"623","author":"J Klein","year":"2023","unstructured":"Klein, J. et al. Distinguishing features of long COVID identified through immune profiling. Nature 623, 139\u2013148 (2023).","journal-title":"Nature"},{"key":"75991_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-41115-3","volume":"13","author":"AC Montezano","year":"2023","unstructured":"Montezano, A. C. et al. SARS-CoV-2 spike protein induces endothelial inflammation via ACE2 independently of viral replication. Sci. Rep. 13, 14086 (2023).","journal-title":"Sci. Rep."},{"key":"75991_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.tim.2023.06.004","volume":"32","author":"L Perico","year":"2023","unstructured":"Perico, L., Benigni, A. & Remuzzi, G. SARS-CoV-2 and the spike protein in endotheliopathy. Trends Microbiol. 32, 53\u201367 (2023).","journal-title":"Trends Microbiol."},{"key":"75991_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn3777","volume":"8","author":"PS Briquez","year":"2022","unstructured":"Briquez, P. S. et al. Severe COVID-19 induces autoantibodies against angiotensin II that correlate with blood pressure dysregulation and disease severity. Sci. Adv. 8, eabn3777 (2022).","journal-title":"Sci. Adv."},{"key":"75991_CR15","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1161\/CIRCULATIONAHA.122.062672","volume":"148","author":"M Cremonesi","year":"2023","unstructured":"Cremonesi, M. et al. Long COVID-19 cardiac complications are associated with autoimmunity to cardiac self-antigens sufficient to cause cardiac dysfunction. Circulation 148, 504\u2013507 (2023).","journal-title":"Circulation"},{"key":"75991_CR16","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1164\/rccm.202108-1903LE","volume":"205","author":"E de Boer","year":"2021","unstructured":"de Boer, E. et al. Decreased fatty acid oxidation and altered lactate production during exercise in patients with post-acute COVID-19 syndrome. Am. J. Respir. Crit. Care Med. 205, 126\u2013129 (2021).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"75991_CR17","doi-asserted-by":"publisher","first-page":"e2236057","DOI":"10.1001\/jamanetworkopen.2022.36057","volume":"5","author":"MS Durstenfeld","year":"2022","unstructured":"Durstenfeld, M. S. et al. Use of cardiopulmonary exercise testing to evaluate long COVID-19 symptoms in adults: a systematic review and meta-analysis. JAMA Netw. Open 5, e2236057 (2022).","journal-title":"JAMA Netw. Open"},{"key":"75991_CR18","doi-asserted-by":"publisher","unstructured":"Rozewicz-Juraszek, M. et al. Native T1 is independently associated with aerobic exercise capacity in long-term follow-up after mild initial COVID-19 disease (Impression COVID&Heart Study). J. Cardiovasc. Magn. Reson. 102725, https:\/\/doi.org\/10.1016\/j.jocmr.2026.102725 (2026).","DOI":"10.1016\/j.jocmr.2026.102725"},{"key":"75991_CR19","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1038\/s41591-022-01837-9","volume":"28","author":"AJ Morrow","year":"2022","unstructured":"Morrow, A. J. et al. A multisystem, cardio-renal investigation of post-COVID-19 illness. Nat. Med. 28, 1303\u20131313 (2022).","journal-title":"Nat. Med."},{"key":"75991_CR20","first-page":"116","volume":"6","author":"S Rajpal","year":"2021","unstructured":"Rajpal, S. et al. Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection. JAMA Cardiol. 6, 116\u2013118 (2021).","journal-title":"JAMA Cardiol."},{"key":"75991_CR21","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1016\/j.jcmg.2020.05.004","volume":"13","author":"L Huang","year":"2020","unstructured":"Huang, L. et al. Cardiac involvement in patients recovered from COVID-2019 identified using magnetic resonance imaging. JACC Cardiovasc. Imaging 13, 2330\u20132339 (2020).","journal-title":"JACC Cardiovasc. Imaging"},{"key":"75991_CR22","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1161\/01.CIR.101.18.2206","volume":"101","author":"C Berry","year":"2000","unstructured":"Berry, C. et al. Investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries. Circulation 101, 2206\u20132212 (2000).","journal-title":"Circulation"},{"key":"75991_CR23","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nrcardio.2014.59","volume":"11","author":"F Jiang","year":"2014","unstructured":"Jiang, F. et al. Angiotensin-converting enzyme 2 and angiotensin 1\u20137: novel therapeutic targets. Nat. Rev. Cardiol. 11, 413\u2013426 (2014).","journal-title":"Nat. Rev. Cardiol."},{"key":"75991_CR24","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahl\u00f6f","year":"2002","unstructured":"Dahl\u00f6f, B. et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet 359, 995\u20131003 (2002).","journal-title":"Lancet"},{"key":"75991_CR25","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner, B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New Engl. J. Med. 345, 861\u2013869 (2001).","journal-title":"New Engl. J. Med."},{"key":"75991_CR26","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","volume":"37","author":"G Gulati","year":"2016","unstructured":"Gulati, G. et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur. Hear. J. 37, 1671\u20131680 (2016).","journal-title":"Eur. Hear. J."},{"key":"75991_CR27","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1093\/eurheartj\/ehac348","volume":"43","author":"C Chimenti","year":"2022","unstructured":"Chimenti, C., Russo, M. A. & Frustaci, A. Immunosuppressive therapy in virus-negative inflammatory cardiomyopathy: 20-year follow-up of the TIMIC trial. Eur. Heart J. 43, 3463\u20133473 (2022).","journal-title":"Eur. Heart J."},{"key":"75991_CR28","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/S0735-1097(99)00048-0","volume":"33","author":"JG Warner","year":"1999","unstructured":"Warner, J. G., Metzger, D. C., Kitzman, D. W., Wesley, D. J. & Little, W. C. Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. J. Am. Coll. Cardiol. 33, 1567\u20131572 (1999).","journal-title":"J. Am. Coll. Cardiol."},{"key":"75991_CR29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","volume":"21","author":"HE Davis","year":"2023","unstructured":"Davis, H. E., McCorkell, L., Vogel, J. M. & Topol, E. J. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 21, 133\u2013146 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"75991_CR30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41581-022-00642-4","volume":"19","author":"N Murakami","year":"2023","unstructured":"Murakami, N. et al. Therapeutic advances in COVID-19. Nat. Rev. Nephrol. 19, 38\u201352 (2023).","journal-title":"Nat. Rev. Nephrol."},{"key":"75991_CR31","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","volume":"355","author":"B Pitt","year":"2000","unstructured":"Pitt, B. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial\u2014the Losartan Heart Failure Survival Study ELITE II. Lancet 355, 1582\u20131587 (2000).","journal-title":"Lancet"},{"key":"75991_CR32","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1001\/jamacardio.2024.2298","volume":"9","author":"JM Madsen","year":"2024","unstructured":"Madsen, J. M. et al. Prehospital pulse-dose glucocorticoid in ST-segment elevation myocardial infarction: the PULSE-MI randomized clinical trial. JAMA Cardiol. 9, 882\u2013891 (2024).","journal-title":"JAMA Cardiol."},{"key":"75991_CR33","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1097\/HJH.0b013e32831daf96","volume":"27","author":"MH Olsen","year":"2009","unstructured":"Olsen, M. H. et al. Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study. J. Hypertens. 27, 567\u2013574 (2009).","journal-title":"J. Hypertens."},{"key":"75991_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf192","volume":"46","author":"J Schulz-Menger","year":"2025","unstructured":"Schulz-Menger, J. et al. 2025 ESC guidelines for the management of myocarditis and pericarditis. Eur. Heart J. 46, ehaf192 (2025).","journal-title":"Eur. Heart J."},{"key":"75991_CR35","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1136\/annrheumdis-2018-213661","volume":"77","author":"L Winau","year":"2018","unstructured":"Winau, L. et al. High-sensitive troponin is associated with subclinical imaging biosignature of inflammatory cardiovascular involvement in systemic lupus erythematosus. Ann. Rheum. Dis. 77, 1590 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"75991_CR36","doi-asserted-by":"publisher","first-page":"101121","DOI":"10.1016\/j.jocmr.2024.101121","volume":"27","author":"VO Puntmann","year":"2024","unstructured":"Puntmann, V. O. et al. Design and rationale of MYOFLAME-19 randomised controlled trial: MYOcardial protection to reduce post-COVID inflammatory heart disease using cardiovascular magnetic resonance endpoints. J. Cardiovasc. Magn. Reson. 27, 101121 (2024).","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"75991_CR37","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.3109\/09638288.2011.635746","volume":"34","author":"EM Goudsmit","year":"2012","unstructured":"Goudsmit, E. M., Nijs, J., Jason, L. A. & Wallman, K. E. Pacing as a strategy to improve energy management in myalgic encephalomyelitis\/chronic fatigue syndrome: a consensus document. Disabil. Rehabil. 34, 1140\u20131147 (2012).","journal-title":"Disabil. Rehabil."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75991-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75991-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75991-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T20:03:49Z","timestamp":1785441829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75991-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["75991"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-75991-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"20 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"V.P. and E.N. are founders of GoetheCVI GmbH. All other authors declare no competing interests. NeoSoft LLC provided in-kind support for imaging software.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"7599"}}